Mass General Brigham, Inc Nurix Therapeutics, Inc. Transaction History
Mass General Brigham, Inc
- $57.1 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding NRIX
# of Institutions
146Shares Held
50MCall Options Held
30.3KPut Options Held
22.7K-
Black Rock Inc. New York, NY4.58MShares$100 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.48MShares$98.4 Million2.6% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$85.2 Million0.72% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$65.8 Million1.46% of portfolio
-
State Street Corp Boston, MA2.73MShares$59.9 Million0.0% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $1.03B
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...